Real-World data reveals how immunotherapy combo performs against lung cancer

NCT ID NCT07526961

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked in everyday hospital practice, not just in strict clinical trials. Researchers measured things like tumor shrinkage, how long patients lived, and what treatments they needed next.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab + Ipilimumab + Chemotherapy
What this could lead to: If successful, this could show how well this drug combination works outside of controlled trials, helping doctors make better treatment decisions for advanced lung cancer.
What could go wrong: This is a retrospective chart review, not a controlled experiment, so results may be influenced by missing data or patient selection. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Wielkopolska Center of Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland

Poznan, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.